UA85394C2 - Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ - Google Patents

Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ

Info

Publication number
UA85394C2
UA85394C2 UAA200604144A UAA200604144A UA85394C2 UA 85394 C2 UA85394 C2 UA 85394C2 UA A200604144 A UAA200604144 A UA A200604144A UA A200604144 A UAA200604144 A UA A200604144A UA 85394 C2 UA85394 C2 UA 85394C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
protein tyrosine
enzyme inhibitors
kinase enzyme
substituted quinolines
Prior art date
Application number
UAA200604144A
Other languages
English (en)
Ukrainian (uk)
Inventor
Алан Виснер
Сридхар Кришна РАБИНДРАН
Хвей-Ру Цоу
Original Assignee
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85394(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет filed Critical Вайет
Publication of UA85394C2 publication Critical patent/UA85394C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

В соответствии с данным изобретением предложены соединения формулы 1, имеющей структуру,где R, R, Rопределены в описании изобретения. Соединения проявляют активность противораковых агентов путем ингибирования рецепторов HER-2 и EGFR.
UAA200604144A 2003-09-15 2003-10-15 Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ UA85394C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15

Publications (1)

Publication Number Publication Date
UA85394C2 true UA85394C2 (ru) 2009-01-26

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200604144A UA85394C2 (ru) 2003-09-15 2003-10-15 Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ

Country Status (7)

Country Link
EP (1) EP1670473A1 (ru)
AU (1) AU2003304497B2 (ru)
BR (1) BR0318503A (ru)
CA (1) CA2537978C (ru)
MX (1) MXPA06002846A (ru)
UA (1) UA85394C2 (ru)
WO (1) WO2005034955A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
PL2010496T3 (pl) * 2006-04-14 2011-01-31 Astrazeneca Ab 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
CN101723854A (zh) 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
AU2010234968B2 (en) 2009-04-06 2015-05-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (zh) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-氰基-6-氨基喹啉类衍生物、其制备方法及其在医药上的应用
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102731395B (zh) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 抗肿瘤药物来那替尼的中间体及其制备与应用
TWI532727B (zh) 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物
CN104926669A (zh) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 反式-4-二甲基胺基巴豆酸盐酸盐的制备方法
EP3677583A4 (en) * 2017-09-01 2021-07-21 Shanghai Pharmaceuticals Holding Co., Ltd. NITROGEN HETEROCYCLIC COMPOUND, MANUFACTURING PROCESS, INTERMEDIATE, COMPOSITION AND USE
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
CN114920695B (zh) * 2022-06-29 2023-06-20 深圳大学总医院 一种喹唑啉衍生物及其制备方法、药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PL370137A1 (en) * 2001-11-27 2005-05-16 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Also Published As

Publication number Publication date
CA2537978A1 (en) 2005-04-21
CA2537978C (en) 2011-08-02
WO2005034955A1 (en) 2005-04-21
AU2003304497B2 (en) 2010-06-24
MXPA06002846A (es) 2006-06-14
EP1670473A1 (en) 2006-06-21
BR0318503A (pt) 2006-09-12
AU2003304497A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
WO2006050109A3 (en) Novel kinase inhibitors
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
IL163781A0 (en) Purine derivatives as kinase inhibitors
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
YU84603A (sh) Novi inhibitori tirozin kinaze
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2007079164A3 (en) Protein kinase inhibitors
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
IN2014DN06567A (ru)
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
UA85505C2 (en) Kinase inhibitors
BRPI0512547A (pt) pirimidinas
IL163777A0 (en) Kinase inhibitors
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS